Target intelligence / Profile preview

Bis(monoacylglycero)phosphate synthase CLN5 (CLN5)

Target
CLN5
Molecular classification
Enzyme, Lysosomal protein
01

Overview

CLN5 is a lysosomal enzyme known as bis(monoacylglycero)phosphate synthase (BMP synthase), essential for the biosynthesis of BMP, a phospholipid crucial for lysosomal membrane integrity, lipid catabolism, and cholesterol homeostasis[1][2][3][4]. CLN5 catalyzes the transacylation of two lysophosphatidylglycerol (LPG) molecules to generate BMP via an energy-independent base exchange reaction; its deficiency results in LPG accumulation and severe BMP depletion, leading to impaired lysosomal lipid metabolism and neurodegenerative disease—most notably, Batten disease (neuronal ceroid lipofuscinosis)[1][2][3][4]. Loss of CLN5 function primarily manifests as a neurodegenerative phenotype, but the enzyme is expressed in multiple tissues and broadly impacts lysosomal function, underpinning its importance in cell biology and disease[1][2]. There are overlapping and compensatory pathways for BMP synthesis mediated by other enzymes, but CLN5 is the main intracellular BMP synthase in many cell types, particularly in the central nervous system[1]. Biomarker changes associated with CLN5 dysfunction include altered BMP and LPG levels and related metabolic phenotypes[4].

Other names
CLN5Ceroid-lipofuscinosis neuronal protein 5Batten disease gene product CLN5Lysosomal bis(monoacylglycero)phosphate synthaseBMP synthase CLN5Bis(monoacylglycero)phosphate synthase CLN5, secreted formCeroid-lipofuscinosis, neuronal 5BMPS
02

Biological functions

Lysosomal lipid metabolismSynthesis of bis(monoacylglycero)phosphate (BMP)Lipid catabolismRegulation of cholesterol homeostasisMaintenance of lysosomal function
03

Disease associations

Neurodegenerative disease (especially neuronal ceroid lipofuscinoses/Batten disease)Lysosomal storage diseasePotential roles in other diseases involving lysosomal dysfunction or lipid dysregulation
04

Safety considerations

Deficiency linked to severe neurodegeneration (Batten disease/neuronal ceroid lipofuscinosis)Lysosomal dysfunctionNo data on direct therapeutic targeting safety concerns
05

Biomarkers

BMP levels in cells/tissuesLysophosphatidylglycerol (LPG) accumulationCLN5 protein/mRNA expressionGlucose uptake impairment, PHGDH as a potential biomarker in Batten disease[4]

Beyond the preview

Go deeper on Bis(monoacylglycero)phosphate synthase CLN5 (CLN5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bis(monoacylglycero)phosphate synthase CLN5 (CLN5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call